Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.
about
Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workersAntiviral drugs for viruses other than human immunodeficiency virusManagement of patients with hepatitis B who require immunosuppressive therapyMultidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolitesPharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infectionMTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartmentsMulticompartmental pharmacokinetic model of tenofovir delivery by a vaginal gelSafety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trialDrug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.Vaginal deployment and tenofovir delivery by microbicide gelsPharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers.A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study.Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.AtriplaR/anti-TB combination in TB/HIV patients. Drug in focusLow-dose tenofovir is more potent than adefovir and is effective in controlling HBV viremia in chronic HBeAg-negative hepatitis B.A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate.Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infectionRenal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimensPharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady stateLinking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolism.Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunctionNew approaches in the management of chronic hepatitis B: role of tenofovir.Accuracy of highly sexually active gay and bisexual men's predictions of their daily likelihood of anal sex and its relevance for intermittent event-driven HIV pre-exposure prophylaxisOptimal Concentration of 2,2,2-Trichloroacetic Acid for Protein Precipitation Based on Response Surface Methodology.Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.Systematic Literature Review and Meta-Analysis of Renal Function in Human Immunodeficiency Virus (HIV)-Infected Patients Treated with Atazanavir (ATV)-Based Regimens.Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infantsInfluence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patientsEffect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults.HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases.Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner.A simple, efficient, and sensitive method for simultaneous detection of anti-HIV drugs atazanavir, ritonavir, and tenofovir by use of liquid chromatography-tandem mass spectrometry.Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function ImpairmentCompared to subcutaneous tenofovir, oral tenofovir disoproxyl fumarate administration preferentially concentrates the drug into gut-associated lymphoid cells in simian immunodeficiency virus-infected macaques.Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women.Multicompartmental Pharmacokinetic Model of Tenofovir Delivery to the Rectal Mucosa by an Enema.
P2860
Q21558500-1F518A99-2955-41B0-A6B0-7197D415234DQ24635330-796A0F6D-CE5C-4D63-B2BE-F607F8B0761BQ26853490-5BDE4F6A-406D-4FE6-B3FD-857F608C75AAQ28289901-92354D3B-5B03-414D-BCB2-81FFEAD26965Q28481276-1EF7ADE8-2C63-43F8-9903-74D935113DF8Q28485356-58AAE09E-B0BD-461F-B573-DDFA671F384DQ28533251-8FA777A9-06AD-4C0C-BC06-9DFA406980DEQ28533828-B14764FA-3153-44C3-AF6A-200767895630Q30249113-F1EB9581-5EFD-4963-8554-D1BD4670655DQ30647900-132EFDFB-494B-4262-B9C7-AEACE882A5BEQ33805141-637D8CD2-6DAD-4D2B-8BC7-0306AD2498ACQ33909720-108CAA32-A0C7-4E79-A28C-629BFC3EACDAQ33938112-3F499829-D060-43EB-81AC-FDA00C874C1DQ34083071-11E30CC7-9645-4AE3-BCDE-4A5F24D32181Q34382099-6A49F37B-2663-44D6-9406-09E7B29678E6Q34414539-8E5023E0-B398-411F-9E7C-AB863915E91CQ34481359-045012B2-0829-41E8-8449-D66EED4A8438Q34488494-D0DAD65E-B570-4BA4-9B9A-0C5270662CCFQ34510726-8E0AFE68-2B1E-42EA-93A0-51384F6D2A19Q34658079-510CF401-7E58-4ED3-BCE2-06C27A087AEFQ35016654-E63B8BBC-5B55-4163-8EB6-EF4C215FE3CFQ35026531-D69D0FA8-FB52-4786-91D9-463EF80C272CQ35102317-0F587E2F-4E03-4C33-A389-0A2008B8EA29Q35154260-5ED495AE-1FD0-4464-9093-857498EDB8ECQ35270776-A028E568-DE79-4AF3-BC62-B130955E7446Q35363649-F75B4D98-16A5-45BB-AFCD-AC5C2FFE2848Q35566732-26AD9F0C-35DF-4CE1-818B-C96E75BBE719Q35598502-02F29AB1-88F9-4E94-BA26-8348618E38CCQ35607723-74CD9F58-CC7D-49BE-BE5E-EF87680543B7Q35791633-98AA20D0-F93B-413C-8D64-DD3A3BBC2D50Q35794988-E41ED902-CC81-40B8-BC24-902CE0322265Q35908584-E0C01564-17F0-4A55-B790-5EC960426406Q36067839-FC169C58-BD7E-4E73-A1F4-FE5CB365F713Q36106256-0EE0EAC2-DE92-4D75-9783-6650713917EBQ36158376-21CCCCC6-97F6-446C-9F3C-34A2BCE47EAFQ36167503-F2A2D07A-5A83-4C20-BFA6-017AFE687698Q36172455-E4ECF76F-8316-42BE-853C-B734CB8F4E38Q36188725-9D0703AC-9E54-4705-8386-76E33A553352Q36243626-72F9519C-A06D-43ED-AE9E-2C44E9154404Q36257669-B63529EB-69CB-4FE8-8FD2-4AE2DBB19857
P2860
Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.
@ast
Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.
@en
type
label
Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.
@ast
Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.
@en
prefLabel
Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.
@ast
Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.
@en
P2093
P1476
Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.
@en
P2093
Brian P Kearney
Jaymin Shah
John F Flaherty
P304
P356
10.2165/00003088-200443090-00003
P577
2004-01-01T00:00:00Z
P6179
1052180346